Home
/
Heart & Cardiovascular

Cholesterol Test: Complete Guide to Results

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

A standard cholesterol test measures total cholesterol, LDL, HDL, and triglycerides — but those numbers only tell part of the story. LDL particle count (apoB) is a stronger predictor of cardiovascular risk than LDL concentration alone, and familial hypercholesterolemia affects 1 in 250 people, driving LDL above 190 mg/dL regardless of lifestyle.

Read more →
Table of contents

Key Takeaways

  • Total cholesterol alone tells an incomplete story, HDL, LDL, and triglycerides each reveal different cardiovascular risks
  • LDL particle number (apoB) matters more than LDL cholesterol concentration for heart disease risk
  • Research suggests HDL above 40 mg/dL (men) or 50 mg/dL (women) may provide cardiovascular protection
  • Studies indicate triglycerides above 150 mg/dL may signal metabolic dysfunction and increased heart disease risk
  • Genetics, diet, exercise, and medications all significantly influence cholesterol levels
  • Advanced testing reveals small, dense LDL particles that may penetrate artery walls more easily

What a Cholesterol Test Means

A cholesterol test measures four key components in your blood. Total cholesterol represents the sum of all cholesterol-carrying particles. LDL cholesterol (low-density lipoprotein) carries cholesterol from your liver to tissues throughout your body. HDL cholesterol (high-density lipoprotein) transports cholesterol back to your liver for processing. Triglycerides are fat molecules that travel alongside cholesterol particles.

Think of LDL as delivery trucks dropping off supplies at construction sites. When you have too many trucks or they're carrying damaged cargo, traffic jams occur. These jams happen inside your artery walls, where research suggests LDL particles can get trapped and trigger inflammation.

HDL particles work like cleanup crews, collecting excess cholesterol from artery walls and hauling it back to your liver for recycling. Studies indicate higher HDL levels may mean more efficient cleanup operations.

Standard cholesterol tests report concentrations in milligrams per deciliter (mg/dL). Total cholesterol below 200 mg/dL is considered desirable. LDL below 100 mg/dL indicates lower cardiovascular risk. HDL above 40 mg/dL for men and 50 mg/dL for women may provide protective benefits. Triglycerides should stay below 150 mg/dL.

But these basic numbers miss crucial details. Advanced testing reveals LDL particle count and size distribution. Research suggests small, dense LDL particles may penetrate artery walls more easily than large, fluffy ones, even at identical cholesterol concentrations.

How to Interpret Your Cholesterol Test

Your cholesterol results work together like puzzle pieces. Start with the HDL-to-total-cholesterol ratio. Divide your HDL by total cholesterol. A higher ratio generally reflects a more favorable lipid profile. For example, if your total cholesterol is 200 mg/dL and HDL is 60 mg/dL, your ratio is 0.30.

Next, examine your triglyceride-to-HDL ratio. Divide triglycerides by HDL. Research indicates the triglyceride-to-HDL ratio is a recognized marker for cardiovascular risk, linked to atherogenic dyslipidemia and insulin resistance. Ratios above 4.0 may signal metabolic dysfunction, even when individual numbers appear normal.

LDL calculations matter too. Standard tests estimate LDL using the Friedewald equation, which becomes inaccurate when triglycerides exceed 400 mg/dL. Direct LDL measurement provides more reliable results in these cases.

Consider your non-HDL cholesterol, total cholesterol minus HDL. This number captures all potentially atherogenic (artery-clogging) particles, including LDL, VLDL, and remnant lipoproteins. Non-HDL below 130 mg/dL indicates lower cardiovascular risk.

Context transforms these numbers. A 45-year-old with LDL of 120 mg/dL, HDL of 35 mg/dL, and triglycerides of 300 mg/dL faces higher risk than someone with identical LDL but HDL of 70 mg/dL and triglycerides of 80 mg/dL.

What Can Influence Your Cholesterol Test

Your genetics load the gun, but lifestyle pulls the trigger. Familial hypercholesterolemia affects 1 in 250 people, causing LDL levels above 190 mg/dL despite healthy habits. These individuals need aggressive management to help reduce the risk of early heart disease. Discuss with your care team.

Diet impacts cholesterol within weeks. Research suggests saturated fats may raise LDL in most people, though individual responses vary dramatically. Trans fats consistently worsen the entire lipid profile, lowering HDL while raising LDL. Simple carbohydrates and added sugars spike triglycerides, especially in insulin-resistant individuals.

Exercise acts like a metabolic reset button. Aerobic and combined exercise training may raise HDL and reduce triglycerides, while resistance training may improve insulin sensitivity, reducing triglyceride production. Even modest weight loss, 5-10 pounds, can improve all cholesterol components.

Medications create predictable changes. Statins may lower LDL by 30-50% at moderate intensity and over 50% at high intensity, depending on type and dose. PCSK9 inhibitors can drop LDL by an additional 46-61%. Fibrates primarily target triglycerides, reducing levels by 20-50%. Beta-blockers may slightly raise triglycerides and lower HDL.

Medical conditions alter cholesterol metabolism. Hypothyroidism may slow cholesterol clearance, raising LDL and total cholesterol. Diabetes may accelerate small, dense LDL formation. Kidney disease may disrupt lipid processing. Liver dysfunction affects cholesterol synthesis and clearance.

Related Context That Changes the Picture

Advanced lipid testing reveals what standard cholesterol tests miss. Lipoprotein(a) or Lp(a) is a genetic variant of LDL that may increase heart attack and stroke risk independent of LDL cholesterol levels. Lp(a) is largely genetically determined and does not meaningfully respond to statin therapy.

ApoB (apolipoprotein B) counts the actual number of atherogenic particles in your blood, regardless of their cholesterol content. Studies suggest ApoB levels in the higher range may indicate greater cardiovascular risk, even when LDL cholesterol appears normal. This measurement becomes crucial for people with metabolic syndrome or diabetes.

Inflammatory markers add another dimension. High-sensitivity C-reactive protein (hs-CRP) measures arterial inflammation. Even with optimal cholesterol levels, research indicates elevated hs-CRP may significantly increase heart disease risk. The combination of high LDL and high hs-CRP may create particularly dangerous cardiovascular conditions.

Insulin resistance transforms cholesterol metabolism. HOMA-IR (insulin resistance index) above 2.5 may indicate metabolic dysfunction that promotes small, dense LDL formation and lowers HDL. Studies suggest fasting insulin levels above 10 μU/mL may suggest similar metabolic problems, even with normal glucose levels.

Homocysteine levels above 15 μmol/L may increase cardiovascular risk independent of cholesterol. This amino acid may damage artery walls, making them more susceptible to cholesterol deposition. B-vitamin deficiencies commonly drive elevated homocysteine levels.

Take Action on Your Cholesterol Insights

Understanding your cholesterol test results is just the beginning. The real power comes from tracking changes over time and connecting these numbers to your broader metabolic picture. Standard cholesterol testing leaves gaps that advanced analysis can fill.

Superpower's Cardiovascular Panel includes comprehensive lipid fractionation with particle size analysis, Lp(a), and inflammatory markers that standard tests miss. You'll discover whether your LDL particles are large and harmless or small and dangerous. You'll learn if genetic factors like elevated Lp(a) require special attention.

Ready to see the complete picture of your cardiovascular health? Order your Cardiovascular Panel today and get the detailed cholesterol analysis that may help you make informed decisions about your heart health future.

FAQs

Cholesterol levels typically change gradually over weeks to months. Triglycerides can fluctuate more rapidly based on recent meals, alcohol intake, or illness. Significant changes in diet, exercise, or medications can alter levels within 6-8 weeks.

HDL (high-density lipoprotein) is considered 'good' because it transports cholesterol away from artery walls back to the liver for processing. LDL (low-density lipoprotein) is labeled 'bad' because it can deposit cholesterol in artery walls, though particle number (apoB) matters more than total LDL cholesterol for cardiovascular risk.

Home cholesterol tests can provide general estimates but lack the precision of laboratory analysis. They typically measure only total cholesterol and may not detect important components like HDL subfractions, particle sizes, or inflammatory markers that influence cardiovascular risk assessment.

References

  1. Morze, J., Melloni, G. E. M., Wittenbecher, C., Ala-Korpela, M., Rynkiewicz, A., Guasch-Ferré, M., Ruff, C. T., Hu, F. B., Sabatine, M. S., & Marston, N. A. (2025). ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. European heart journal, 46(27), 2691-2701. https://doi.org/10.1093/eurheartj/ehaf207
  2. Meshkani, R., & Adeli, K. (2009). Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clinical biochemistry, 42(13-14), 1331-46. https://doi.org/10.1016/j.clinbiochem.2009.05.018
  3. Akar, G., Sengul-Bag, F., Akyurek, F., & Ozturk, B. (2026). Investigation of the relationship between trimethylamine N-oxide, CD36, and CD38 levels in individuals with a high triglyceride/HDL-cholesterol ratio. Scandinavian journal of clinical and laboratory investigation, 86(1), 42-52. https://doi.org/10.1080/00365513.2026.2616760
  4. Bansal, M., Kaushal, P., Kasliwal, R. R., Chandra, P., Kapoor, R., Chouhan, N., Bhan, A., & Trehan, N. (2026). Different Methods of Low-density Lipoprotein Cholesterol Estimation and the Impact on Lipid-lowering Therapy in Patients with Coronary Artery Disease. The Journal of the Association of Physicians of India, 74(2), 57-61. https://doi.org/10.59556/japi.74.1344
  5. Schunkert, H., Natarajan, P., & Samani, N. J. (2026). The Inherited Basis of Coronary Artery Disease. The New England journal of medicine, 394(6), 576-587. https://doi.org/10.1056/NEJMra2405153
  6. Astrup, A., Magkos, F., Bier, D. M., Brenna, J. T., de Oliveira Otto, M. C., Hill, J. O., King, J. C., Mente, A., Ordovas, J. M., Volek, J. S., Yusuf, S., & Krauss, R. M. (2020). Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 76(7), 844-857. https://doi.org/10.1016/j.jacc.2020.05.077
  7. Chen, H., Sheng, X., & Chen, J. (2026). Effects of different exercise interventions on lipid profiles in patients with stable coronary artery disease: a systematic review and network meta-analysis. European journal of physical and rehabilitation medicine, 62(1), 78-88. https://doi.org/10.23736/S1973-9087.26.09237-3
  8. Császár, A. (2019). The characteristics of two LDL-cholesterol level reduction treatment strategies, "treat-to-target" and "percent reduction": an observational study without intervention. BMC cardiovascular disorders, 19(1), 57. https://doi.org/10.1186/s12872-019-1038-y
  9. Imran, T. F., Khan, A. A., Has, P., Jacobson, A., Bogin, S., Khalid, M., Khan, A., Kim, S., Erqou, S., Choudhary, G., Aspry, K., & Wu, W. C. (2023). Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PloS one, 18(12), e0295359. https://doi.org/10.1371/journal.pone.0295359
  10. Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016). Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 11(11), CD009753. https://doi.org/10.1002/14651858.CD009753.pub2
  11. Wang, Q., Zhang, X., Wu, F., & Qi, X. (2026). The study on serum oxidized low-density lipoprotein and homocysteine as cardiovascular risk markers in subclinical hypothyroidism patients. Frontiers in endocrinology, 17, 1750486. https://doi.org/10.3389/fendo.2026.1750486
  12. Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., Drechsler, C., Wanner, C., Mora, S., Lesogor, A., & Tsimikas, S. (2018). Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet (London, England), 392(10155), 1311-1320. https://doi.org/10.1016/S0140-6736(18)31652-0
  13. Kazibwe, R., Schaich, C. L., Kingsley, J. A., Chevli, P., Mirzai, S., Rikhi, R., Masrouri, S., Slipczuk, L., & Shapiro, M. D. (2026). Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors. European journal of preventive cardiology. https://doi.org/10.1093/eurjpc/zwag221
  14. Moretti, R., & Caruso, P. (2019). The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. International journal of molecular sciences, 20(1). https://doi.org/10.3390/ijms20010231
  15. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e563-e595. https://doi.org/10.1161/CIR.0000000000000677
  16. Fatima, S., Ijaz, A., Sharif, T. B., Khan, D. A., & Siddique, A. (2016). Accuracy of Non-Fasting Lipid Profile for the Assessment of Lipoprotein Coronary Risk. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 26(12), 954-957. https://pubmed.ncbi.nlm.nih.gov/28043305/

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey